Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$135.29 USD
-0.16 (-0.12%)
Updated Jun 17, 2024 04:00 PM ET
After-Market: $135.29 0.00 (0.00%) 4:26 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Brokerage Reports
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 1 - 20 ( 309 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Passing The Torch: NBIX Announces CEO Succession Plan
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Expectations Surrounding PANSS Scale for NBI-568?s Phase 2 Readout; PT Up to $160
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Solid Ingrezza Performance, As Additional Pipeline Readouts On Deck
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Positive Topline SAVITRI Data Set Up NBI-845 for Potential Win in MDD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Nice Pipeline Win Heading Into Earnings; ''845 MDD Hits
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Focusing on Importance of PK and Safety for Topline Data of ?568?Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Onward As NBIX Sets Stage With FY24 Guidance, Near-Term Crinecerfont Filing
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Kickstart or False Start? What January Tells Us about Biotech Annual Returns
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurocrine Shifts Focus Towards Neurology, Eyeing at Movement Disorder Diseases and Psychosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
If Cash Is King In Biotech, Pipelines Are The Queens
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
KOL Call Invite: Epilepsy KOL Check - AES Wrap and Thoughts Into 2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for NBIX 112223
Provider: Stock Traders Daily
Analyst: Research Department